Status:
COMPLETED
Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer
Lead Sponsor:
Odense University Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
NA
Brief Summary
Prostate cancer is currently the leading newly diagnosed cancer in the industrialized world. Treatment of prostate cancer is highly dependent on the stage of the disease. Current methods for staging o...
Detailed Description
1. Introduction. Cancer of the prostate (PCa) is currently the leading newly diagnosed cancer and the second most common cause of cancer deaths among men in the industrialized world . In Denmark alone...
Eligibility Criteria
Inclusion
- Newly diagnosed, histologically verified PCa and
- Written consent and
- Planned extended lymph node dissection and
- PSA ≥ 20 ng/mL and/or
- Gleason score \> 7 and/or
- cT-stage ≥ cT2c
Exclusion
- Withdrawal of consent or
- Other active malign disease
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02232724
Start Date
November 1 2014
End Date
February 1 2018
Last Update
October 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospiatal
Odense, Denmark, 5000